Association of Clinical Characteristics, Antidiabetic and Cardiovascular Agents With Diabetes Mellitus and Covid-19: A 7-Month Follow-Up Cohort Study Publisher



Pazoki M¹ ; Chichagi F² ; Hadadi A³ ; Kafan S¹ ; Montazeri M³ ; Kazemian S^{4, 5} ; Aminorroaya A⁶ ; Ebrahimi M⁷ ; Ashraf H^{2, 5} ; Hazaveh MM⁷ ; Khajavi MR⁸ ; Moharari RS⁸ ; Sharifnia SH⁸ ; Saleh SK⁹ Show All Authors
Source: Journal of Diabetes and Metabolic Disorders Published:2021

Abstract

Background: The prognostic factors of long-term outcomes in hospitalized patients with diabetes mellitus and COVID-19 are lacking. Methods: In this retrospective cohort study, we evaluated patients aged ≥ 18-years-old with the COVID-19 diagnosis who were hospitalized between Feb 20 and Oct 29, 2020, in the Sina Hospital, Tehran, Iran. 1323 patients with COVID-19 entered in the final analysis, of whom 393 (29.7%) patients had diabetes. We followed up patients for incurring in-hospital death, severe COVID-19, in-hospital complications, and 7-month all-cause mortality. By doing univariate analysis, variables with unadjusted P-value < 0.1 in univariate analyses were regarded as the confounders to include in the logistic regression models. We made adjustments for possible clinical (model 1) and both clinical and laboratory (model 2) confounders. Results: After multivariable regression, it was revealed that preadmission use of sulfonylureas was associated with a borderline increased risk of severity in both models [model 1, OR (95% CI):1.83 (0.91–3.71), P-value: 0.092; model 2, 2.05 (0.87–4.79), P-value: 0.099] and major adverse events (MAE: each of the severe COVID-19, multi-organ damage, or in-hospital mortality) in model 1 [OR (95% CI): 1.86 (0.90–3.87), P-value: 0.094]. Preadmission use of ACEIs/ARBs was associated with borderline increased risk of MAE in the only model 1 [OR (95% CI):1.83 (0.96–3.48), P-value: 0.066]. Conclusions: Preadmission use of sulfonylureas and ACEIs/ARBs were associated with borderline increased risk of in-hospital adverse outcomes. © 2021, Springer Nature Switzerland AG.